$-0.09 EPS Expected for Amarin Corporation plc (AMRN)

October 14, 2018 - By Marie Mckinney

Amarin Corporation plc (NASDAQ:AMRN) LogoInvestors sentiment increased to 1.44 in 2018 Q2. Its up 0.39, from 1.05 in 2018Q1. It improved, as 19 investors sold Amarin Corporation plc shares while 15 reduced holdings. 15 funds opened positions while 34 raised stakes. 101.63 million shares or 10.31% less from 113.30 million shares in 2018Q1 were reported.
Rbf Lc holds 0.01% of its portfolio in Amarin Corporation plc (NASDAQ:AMRN) for 33,700 shares. 18,293 are held by Bluecrest Cap Mngmt. Moreover, Architects has 0.01% invested in Amarin Corporation plc (NASDAQ:AMRN). Raymond James Fincl Advsr Inc holds 0% or 284,915 shares. Apriem Advisors holds 0.01% or 7,618 shares. Invesco has 0% invested in Amarin Corporation plc (NASDAQ:AMRN) for 2.00M shares. Fmr Limited Liability reported 0% in Amarin Corporation plc (NASDAQ:AMRN). Bb&T Secs Ltd Company has 15,369 shares. Health Value Ltd invested in 4.38% or 500,000 shares. Jpmorgan Chase holds 1,000 shares. Comerica Bank, Michigan-based fund reported 15,816 shares. Consonance Capital Management L P invested in 4.97M shares. 134,207 are held by Td Asset Mgmt Inc. Proshare Advsr Limited owns 122,388 shares. Great Point Prns Limited Com invested 0.45% in Amarin Corporation plc (NASDAQ:AMRN).

Since June 30, 2018, it had 0 buys, and 1 insider sale for $80,955 activity.

Analysts expect Amarin Corporation plc (NASDAQ:AMRN) to report $-0.09 EPS on November, 7.They anticipate $0.05 EPS change or 125.00 % from last quarter’s $-0.04 EPS. After having $-0.12 EPS previously, Amarin Corporation plc’s analysts see -25.00 % EPS growth. The stock increased 1.76% or $0.34 during the last trading session, reaching $19.65. About 20.28 million shares traded or 54.48% up from the average. Amarin Corporation plc (NASDAQ:AMRN) has declined 3.76% since October 14, 2017 and is downtrending. It has underperformed by 19.38% the S&P500.

Amarin Corporation plc (NASDAQ:AMRN) Ratings Coverage

Among 4 analysts covering Amarin (NASDAQ:AMRN), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Amarin had 4 analyst reports since May 2, 2018 according to SRatingsIntel. The firm earned “Buy” rating on Thursday, May 3 by H.C. Wainwright. The stock of Amarin Corporation plc (NASDAQ:AMRN) earned “Buy” rating by Jefferies on Tuesday, September 25. The firm earned “Buy” rating on Tuesday, September 25 by Citigroup. The rating was maintained by Cantor Fitzgerald with “Buy” on Wednesday, May 2.

Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. The company has market cap of $5.78 billion. The company's lead product is Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It currently has negative earnings. It is also involved in developing Vascepa for the treatment of patients with high triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol levels.

More notable recent Amarin Corporation plc (NASDAQ:AMRN) news were published by: Fool.com which released: “2 Healthcare Stocks That Soared in September: Can They Keep Climbing?” on October 02, 2018, also Nasdaq.com with their article: “Pre-Market Most Active for Sep 25, 2018 : AMRN, SNAP, IBN, DLR, FB, AZN, TLRY, CRON, ABX, BP, QQQ, VSTM” published on September 25, 2018, Seekingalpha.com published: “What If Amarin’s REDUCE-IT Trial Fails?” on September 17, 2018. More interesting news about Amarin Corporation plc (NASDAQ:AMRN) were released by: Seekingalpha.com and their article: “Amarin ‘Proves It'” published on September 24, 2018 as well as Fool.com‘s news article titled: “Why Amarin Stock Skyrocketed 415% in September” with publication date: October 09, 2018.

Amarin Corporation plc (NASDAQ:AMRN) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.